SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Elevation Oncology, Inc. (ELEV) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+2365.8%).
- Analyst consensus target $9.00 (+2365.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 40/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ELEV
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.78
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$9.00 (+2365.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.25 |
$0.00 |
$-5.88M |
- |
| 2020 |
$-0.73 |
$0.00 |
$-17.27M |
- |
| 2021 |
$-1.38 |
$0.00 |
$-32.04M |
- |
| 2022 |
$-4.09 |
$0.00 |
$-95.08M |
- |
| 2023 |
$-1.34 |
$0.00 |
$-45.7M |
- |
| 2024 |
$-0.78 |
$0.00 |
$-44.49M |
- |
